OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovery Science & Technology, Amsterdam 12-14 July, 2023
Oxcia’s CEO Ulrika Warpman Berglund has been invited to present “OXC-101: A Novel Way to Treat Acute Myeloid Leukemia by Inducing Mitotic Arrest, ROS and Oxidative Damage” at the 18[th] Annual Congress of International Drug Discovery Science & Technology (IDDST) conference, Amsterdam, the Netherlands, July 12-14, 2023. OXC-101 is a mitotic MTH1 inhibitor, with a unique synergistic dual mechanism of action. It arrests cancer cells in mitosis by disturbing microtubule polymerization, thereby accumulating ROS which in turn generates e.g. oxidized nucleotides. By inhibiting the enzyme MTH1,